A Randomized, Double-Blind, Placebo-Controlled Study of Benfluorex in HIV-Infected Patients with Insulin Resistance or Impaired Glucose Tolerance

REFERENCES

• Despres JP, Lamarche B, Mauriege P, et al. Hyperinsu-linemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952–957.
   PubMed Web of Science ®Google Scholar
• Haffner SM, Mykkanen L, D'Agostino Jr R, et al. Insulin sensitivity in subjects with type 2 diabetes: Relationship to cardiovascular risk factors: The Insulin Resistance Athero-sclerosis Study. Diabetes Care. 1999;22:562–568.
   PubMed Web of Science ®Google Scholar
• Cruz ML, Bergman RN, Goran MI. Unique effect of vis-ceral fat on insulin sensitivity in obese Hispanic children with a family history of type 2 diabetes. Diabetes Care. 2002;25:1631–1636.
   PubMed Web of Science ®Google Scholar
• Poizot-Martin I, Marimoutou C, Di Stephano D, et al. Vis-ceral fat-mass in 175 HAART-treated HIV-infected patients. Antiviral Ther 2005;10:L22.
   Web of Science ®Google Scholar
• Knowler WC, Barett-Connor E, Fowler WE, et al. Reduc-tion in the incidence of type 2 diabetes with lifetstyle inter-vention or metformin. N Engl J Med. 2002;346:393–403.
   PubMed Web of Science ®Google Scholar
• Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystro-phy syndrome: A randomized controlled trial. J Am Med Assoc. 2000;284:472–477.
   PubMed Web of Science ®Google Scholar
• Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomised, double-blind, placebo-controlled trial. Lancet. 2004;363:429–438.
   PubMed Web of Science ®Google Scholar
• Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: A randomized, controlled trial. Ann Intern Med. 2004;140:786–794.
   PubMed Web of Science ®Google Scholar
• Sutinen J, Hakkinen AM, Westerbacka J, et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy—a randomized double-blind placebo-controlled study. Antivir Ther 2003;8:199–207.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard BG. Hyperlactataemia and lactic acidosis during antiretroviral therapy: Relevance, reproducibility and pos-sible risk factors. AIDS. 2002;16:1341–1349.
   PubMed Web of Science ®Google Scholar
• van Wijk JP, de Koning EJ, Cabezas MC, et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: A randomized trial. Ann Intern Med. 2005;143: 337–346.
   PubMed Web of Science ®Google Scholar
• Derosa G, D'Angelo A, Ragonesi PD, et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006;31:375–383.
   PubMed Web of Science ®Google Scholar
• Mulligan K, Yang Y, Wininger DA, et al. Effects of metformin and rosiglitazone in HIV-infected patients with hyperin-sulinemia and elevated waist/hip ratio. AIDS. 2007;21: 47–57.
   PubMed Web of Science ®Google Scholar
• Broussole C, Coste M, GuillIon-Metz F, et al. Comparaison de l'action antidiabétique du benfluorex et de la met-formine. Etude multicentrique. Sem Hop Paris. 1988;64: 3153–3165.
   Google Scholar
• Moulin P, Andre M, Alawi H, et al. Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: An 18-week, randomized, double-blind study. Diabetes. 2006;29:515–520.
   Web of Science ®Google Scholar
• Del Prato S, Erkelens DW, Leutenegger M. Six-month effi-cacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients. Acta Diabetol. 2003;40:20–27.
   PubMed Web of Science ®Google Scholar
• Poizot-Martin I, Marimoutou C, Vion-Dury F, et al. Benfluo-rex as a therapeutic option for insulin resistance in HIV-lipodystrophy syndrome. HIV Clin Trials. 2004;5:86–90.
   PubMed Web of Science ®Google Scholar
• Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998;6:47–53.
   PubMedGoogle Scholar
• Cigolini M, Targher G, Bergamo Andreis IA, Tonoli M, Agostino G, De Sandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol. 1996;16:368–374.
   PubMed Web of Science ®Google Scholar
• Juhan-Vague I, Alessi MC, Morange PE. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med. 2000;32(Suppl 1): 78–84.
   PubMed Web of Science ®Google Scholar
• He G, Andersen O, Haugaard SB, et al. Plasminogen acti-vator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines. Eur J Clin Invest. 2005;35:583–590.
   PubMed Web of Science ®Google Scholar
• Hadigan C, Meigs JB, Rabe J, et al. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab. 2001;86:939–943.
   PubMed Web of Science ®Google Scholar
• Ribera RJ, Munoz CR, Ferrando AN, Sahun BN, Cels CA, Capamany PR. Valvular heart disease associated with benfluorex. Rev Esp Cardiol. 2003;56:215–216.
   PubMed Web of Science ®Google Scholar
• Noize P, Sauer M, Bruneval P, et al. Valvular heart disease in a patient taking benfluorex. Fundam Clin Pharmacol. 2006;20:577–578.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Lascoux-lacombe C, Delfraissy JF, et al. Preva-lence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med. 2008;177:108–113.
   PubMed Web of Science ®Google Scholar
• Triant VA, Lee H, Hadigan C, Grinpoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus dis-ease. J Clin Endocrinol Metab. 2007;92:2506–2412.
   PubMed Web of Science ®Google Scholar